Home
Per Eystein Lønning's picture

Per Eystein Lønning

Professor
  • E-mailPer.Lonning@uib.no
  • Phone+47 55 97 20 10+47 55 97 20 27
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning is the head of the breast cancer research group at Mohn cancer research laboratory. he has a continuous work record in cancer therapy and science since 1982. He was employed as a consultant in oncology at Haukeland University Hospital in 1990, and became professor at the University of Bergen in 1992. The breast cancer group currently includes about 20 members. The work is centered on translational research in breast cancer; the group however also runs projects related to colorectal cancers and melanomas. The team include senior researchers 7 postdocs / PhD candidates as well as technical staff members in the laboratory but also physicians seeing patients at the Department of Oncology, several of whom in addition work part-time on their projects in the laboratory. Professor Lønnings main area of interest has been mechanism related to therapy failure in the area of endocrine as well as chemotherapy for breast cancer. In addition, he has had an interest in genetic and epigenetic cancer risk factors. His current main field of research relates to chemotherapy resistance.

Academic article
  • Haynes, Ben P.; Straume, Anne Hege; Geisler, Jurgen; A'Hern, Roger; Helle, Hildegunn; Smith, Ian E; Lønning, Per Eystein; Dowsett, Mitch. 2010. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
  • Geisler, Jurgen; Lønning, Per Eystein. 2010. Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
  • Jönsson, Göran; Busch, Christian; Knappskog, Stian; Geisler, Jürgen; Miletic, Hrvoje; Ringnér, Markus; Lillehaug, Johan R.; Borg, Åke; Lønning, Per Eystein. 2010. Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
  • Lønning, Per Eystein. 2010. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. S19-S30.
  • Lønning, Per Eystein; Geisler, Jürgen. 2010. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 288-293.
  • Dejeux, Emelyne; Rønneberg, Jo Anders; Solvang, Hiroko Kato; Bukholm, Ida R. K.; Geisler, Stephanie; Aas, Turid; Gut, Ivo G.; Børresen-Dale, Anne-Lise; Lønning, Per Eystein; Kristensen, Vessela Nedelcheva ; Tost, Jörg. 2010. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 13 pages.
  • Berge, Elisabet Ognedal; Staalesen, Vidar; Straume, Anne Hege; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 386-395.
  • Geisler, Jurgen; Suzuki, Takashi; Helle, Hildegunn; Miki, Yasuhiro; Nagasaki, Shuji; Duong, Nhat Kim; Ekse, Dagfinn; Aas, Turid; Evans, Dean B.; Lønning, Per Eystein; Sasano, Hironobu. 2010. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
  • Lønning, Per Eystein; Helle, Hildegunn; Duong, Nhat Kim; Ekse, Dagfinn; Aas, T; Geisler, Jurgen. 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
  • Lønning, Per Eystein. 2009. Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research.
  • Hauglid, Marianne; Moi, Line Leonore Haugan; Dixon, J. Michael; Geisler, Jurgen; Lien, Ernst Asbjørn; Miller, William Russell; Lønning, Per Eystein; Mellgren, Gunnar. 2009. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • Lønning, Per Eystein. 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • Røsland, Gro Vatne; Svendsen, Agnete; Torsvik, Anja; Sobala, Ewa; McCormack, Emmet Martin; Immervoll, Heike ; Mysliwietz, Josef; Tonn, Jörg Christian ; Goldbrunner, Roland; Lønning, Per Eystein; Bjerkvig, Rolf; Schichor, Christian. 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • Glynn, Sharon A.; Boersma, Brenda J.; Howe, Tiffany M.; Edvardsen, Hege; Geisler, Stephanie; Goodman, Julie E.; Ridnour, Lisa A.; Lønning, Per Eystein; Børresen-Dale, Anne-Lise ; Naume, Bjørn; Kristensen, Vessela Nedelcheva ; Chanock, Stephen J.; Wink, David A.; Ambs, Stefan. 2009. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 4165-4173.
  • Chekenya, Martha; Krakstad, Camilla; Svendsen, Agnete; Netland, Inger Anne; Staalesen, Vidar; Tysnes, Berit Bølge; Selheim, Frode; Wang, Jian; Sakariassen, Per Øystein; Sandal, Tone; Lønning, Per Eystein; Flatmark, Torgeir; Enger, Per Øyvind; Bjerkvig, Rolf; Sioud, M; Stallcup, William B. 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • Nordgard, Silje H.; Alnaes, GIG; Hihn, Björn; Lingjærde, Ole Chr.; Liestøl, Knut; Tsalenko, Anya; Sørlie, Therese; Lonning, PE; Børresen-Dale, Anne-Lise; Kristensen, Vessela Nedelcheva. 2008. Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 577-585.
  • Geisler, Jurgen; Helle, Hildegunn; Ekse, D.; Duong, Nhat Kim; Evans, Dean B.; Nordbø, Yngve; Aas, Turid; Lønning, Per Eystein. 2008. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
  • Rønneberg, Jo Anders; Tost, Jörg; Solvang, Hiroko K.; Alnæs, Grethe Irene Grenaker; Johansen, Fredrik E.; Brendeford, Ellen M.; Yakhini, Zohar; Gut, Ivo G.; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Gabrielsen, Odd Stokke; Kristensen, Vessela Nedelcheva. 2008. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research. 5562-5571.
  • Lønning, Per Eystein. 2008. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
  • Lønning, Per Eystein; Geisler, Jurgen. 2008. Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 987-997.
  • Lønning, Per Eystein. 2008. Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 388-390.
  • Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet Ognedal; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise Olaug; Engebretsen, Lars Fredri; Lillehaug, Johan; Lønning, Per Eystein. 2008. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. 15 pages.
  • Lønning, Per Eystein; Geisler, Jurgen. 2008. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 196-202.
  • Miller, William R.; Bartlett, John; Brodie, Angela MH; Brueggemeier, Robert W; Di Salle, Enrico; Lønning, Per Eystein; Llombart, Antonio; Maass, Nicolai; Maudelonde, Thierry; Sasano, Hironobu; Goss, Paul E. 2008. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 829-837.
  • Geisler, Jurgen; Ekse, Dagfinn; Helle, Hildegunn; Duong, Nhat Kim; Lønning, Per Eystein. 2008. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology. 90-95.
  • Norum, Jan; Olsen, Jan Abel; Wist, Erik; Lonning, PE. 2007. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica.
  • Geisler, Jurgen; Haynes, Ben; Ekse, Dagfinn; Dowsett, Mitch; Lønning, Per Eystein. 2007. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
  • Coombes, R. Charles; Kilburn, Lucy S.; Snowdon, Claire F.; Paridaens, Robert; Coleman, Ronert E.; Jones, Stephen E.; Jassem, Jacek; Van de Velde, Cornelis J.H.; Delozier, Thierry; Álvarez , Inmaculada; Del Mastro, Lucia; Ortmann, Olaf; Diedrich, Klaus; Coates, Alan S.; Bajetta, Emilio; Holmberg, Stig B.; Dodwell, David; Mickiewicz, Elizabeth; Andersen, Jesper; Lønning, Per Eystein; Cocconi, Giorgio; Forbes, John; Castiglione, Monica; Stuart, Nick; Stewart, Alan; Fallowfield, Lesley J.; Bertelli, Gian; Hall, Emma; Bogle, Richard G.; Carpentieri, Mary; Colajori, Elena; Subar, Milayna; Ireland, Elizabeth; Bliss, Judith M. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
  • Grudic, Amra; Jul-Larsen, Åsne; Haring, SJ; Wold, MS; Lønning, Per Eystein; Bjerkvig, Rolf; Bøe, Stig Ove. 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • Grudic, Amra; Jul-Larsen, Åsne; Haring, Stuart J.; Wold, Marc S.; Lønning, Per Eystein; Bjerkvig, Rolf; Bøe, Stig Ove. 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • Knappskog, Stian; Chrisanthar, Ranjan; Staalesen, Vidar; Børresen-Dale, Anne-Lise; Gram, Inger Torhild; Lillehaug, Johan Richard; Lønning, Per Eystein. 2007. Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 908-910.
  • Lønning, Per Eystein. 2007. Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. viii3-viii7.
  • Lønning, Per Eystein; Geisler, Jurgen. 2007. Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 55-61.
  • Lønning, Per Eystein. 2007. Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 223-238.
  • Nordgard, Silje H.; Ritchie, Marylyn D.; Jensrud, Sigrid D.; Motsinger, Alison A.; Alnaes, GIG; Lernmon, Gordon; Berg, Marianne; Gelsler, S; Moore, Jason H.; Lonning, PE; Børresen-Dale, Anne-Lise; Kristensen, Vessela Nedelcheva. 2007. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 127-136.
  • Monstad, Sissel Evy; Storstein, Anette Margrethe; Dørum, Anne; Knudsen, Anette; Lønning, Per Eystein; Salvesen, Helga; Aarseth, Jan Harald; Vedeler, Christian A. 2006. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 53-58.
  • Staalesen, Vidar; Knappskog, Stian; Chrisanthar, Ranjan; Nordgard, Silje H.; Løkkevik, Erik; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Gram, Inger Torhild; Kristensen, Vessela N; Børresen-Dale, Anne-Lise; Lillehaug, Johan Richard; Lønning, Per Eystein. 2006. The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 6000-6004.
  • Knudsen, Anette; Monstad, Sissel Evy; Dørum, Anne; Lønning, Per Eystein; Salvesen, Helga; Drivsholm, Lars; Aarseth, Jan Harald; Vedeler, Christian A. 2006. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 1280-1284.
  • Bøe, Stig Ove; Haave, Marte; Jul-Larsen, Åsne; Grudic, Amra; Bjerkvig, Rolf; Lønning, Per Eystein. 2006. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 3284-3295.
  • Sørlie, Therese; Perou, Charles M.; Fan, Cheng; Geisler, Stephanie; Aas, Turid; Nobel, Andrew; Anker, Gun; Akslen, Lars A.; Botstein, David; Børresen-Dale, Anne-Lise; Lønning, Per Eystein. 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • Baumbusch, Lars Oliver; Myhre, Simen; Langerød, Anita; Bergamaschi, Anna; Geisler, Stephanie B; Lønning, Per Eystein; Deppert, Wolfgang; Dornreiter, Irene; Børresen-Dale, Anne-Lise. 2006. Expression of full-length p35 and its isoform DELTAp53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular Cancer. 47.
  • Muggerud, Aslaug Aamodt; Johnsen, Hilde; Barnes, Debra A.; Steel, Adam; Lønning, Per Eystein; Lonning, PE; Sørlie, Therese; Naume, Bjørn; Børresen-Dale, Anne-Lise. 2006. Evaluation of MetriGenix custom 4D (TM) arrays applied for detection of breast cancer subtypes. BMC Cancer. 6 pages.
  • Lønning, Per Eystein. 2006. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology. 217-225.
  • Lønning, Per Eystein; Geisler, Jürgen. 2006. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 356-357.
  • Geisler, J; Lønning, Per Eystein; Krag, LE; Løkkevik, Erik; Risberg, Terje; Hagen, AI; Schlichting, E; Lien, EA; Øfjord, Erik S.; Eide, GE; Di Salle, Enrico; di Salle, E; Paolini, J. 2006. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • Thorsen, Frits Alan; Afione, Sandra; Huszthy, Peter Csaba; Tysnes, Berit Bølge; Svendsen, Agnete; Bjerkvig, Rolf; Kotin, Robert M.; Lønning, Per Eystein; Hoover, Frank. 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
  • Knappskog, Stian; Geisler, Jürgen; Arnesen, Thomas; Lillehaug, Johan; Lønning, Per Eystein. 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 1155-1163.
  • Jeffrey, SS; Lønning, Per Eystein; Hillner, BE. 2005. Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
  • Lønning, Per Eystein; Sørlie, T; Børresen-Dale, Anne-Lise. 2005. Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
  • Kristensen, Vessela Nedelcheva ; Sørlie, Therese; Geisler, E; Yoshimura, Noriko; Lingjærde, Ole Christian; Glad, Ingrid; Frigessi, Arnoldo ; Harada, Nobuhiro; Lonning, PE; Børresen-Dale, Anne-Lise. 2005. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 105-111.
  • Joensuu, Heikki; Ejlertsen, Bent; Lønning, Per Eystein; Rutqvist, Lars-Erik. 2005. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
  • Lønning, Per Eystein; Geisler, Jürgen. 2005. Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
  • Jul-Larsen, Åsne; Visted, T; Karlsen, BO; Rinaldo, Christine H; Bjerkvig, R; Lønning, Per Eystein; Bøe, Stig Ove. 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 58-73.
  • Usary, Jerry; Llaca, Victor; Karaca, Gamze; Presswala, Shafaq; Karaca, Mehmet; He, Xiaping; Langerød, Anita; Kåresen, Rolf; Oh, Daniel S; Dressler, Lynn G; Lønning, Per Eystein; Strausberg, Robert l; Chanock, Stephen; Børresen-Dale, Anne-Lise ; Perou, Charles M. 2004. Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • Staalesen, Vidar; Falck, Jacob; Geisler, Stephanie; Bartkova, Jirina; Børresen-Dale, Anne-Lise ; Lukas, Jiri; Lillehaug, Johan Richard; Bartek, Jiri; Lønning, Per Eystein. 2004. Alternative splicing and mutation status of CHEK2 in stag III breast cancer. Oncogene. 8535-8544.
  • Geisler, S.; Børresen-Dale, Anne-Lise; Johnsen, Hilde; Aas, Turid; Geisler, J.; Akslen, Lars A.; Anker, G.; Lønning, Per Eystein. 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Sørlie, Therese; Tibshirani, R.; Parker, J; Hastie, T; Marron, J.S.; Nobel, A; Deng, S; Johnsen, Hilde; Pesich, R; Geisler, S.; Perou, C. M.; Lønning, Per Eystein; Brown, P. O; Børresen-Dale, Anne-Lise; Ørstavik, Karen Helene. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • Aas, Turid; Geisler, S.; Eide, Geir Egil; Faksvåg Haugen, Dagny; Varhaug, Jan Erik; Basøe, A. M; Thorsen, T; Børresen-Dale, Anne-Lise; Lønning, Per Eystein; Akslen, Lars A. 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Lønning, Per Eystein. 2002. The role of aromatase inactivators in the treatment of breast cancer. International Journal of Clinical Oncology. 265-270.
  • Helle, Svein Inge; Ekse, Dagfinn; Holly, Jeff M. P.; Lønning, Per Eystein. 2002. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. Journal of Steroid Biochemistry and Molecular Biology. 95-102.
  • Buzdar, Aman; Hayes, Daniel; El-Khoudary, Ahmed; Yan, Sin; Lønning, Per Eystein; Lichinitser, Michael; Gopal, Rupah; Falkson, Geoffrey; Pritchard, Kathleen; Lipton, Alan; Wolter, Kevin; Lee, Andrew; Fly, Kolette; Chew, Ritchard; Alderdice, Maurice; Burke, K.; Eisenberg, Peter. 2002. Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 161-175.
  • Helle, Svein Inge; Ueland, Tor; Ekse, Dagfinn; Frøland, Stig S.; Holly, Jeffrey M.P.; Lønning, Per Eystein; Aukrust, Pål. 2001. The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism. 227-233.
  • Geisler, Jürgen; Lønning, Per Eystein. 2001. Resistance to Endocrine Therapy of Breast Cancer: Recent Advances and Tomorrow`s Challenges. Clinical Breast Cancer. 297-308.
  • Jain, Ajay N.; Chin, Koei; Børresen-Dale, Anne-Lise; Erikstein, Bjorn K.; Lønning, Per Eystein; Kaaresen, Rolf; Gray, Joe E. 2001. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 7952-7957.
  • Helle, Svein Inge; Geisler, Stephanie; Aas, Turid; Paulsen, T.; Holly, Jeffrey M.P.; Lønning, Per Eystein. 2001. Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. British Journal of Cancer. 74-77.
  • Lønning, Per Eystein; Geisler, Jürgen; Johannessen, Dag Clement; Gschwind, Hans-Peter; Waldmeier, Felix; Schneider, Werner; Galli, Bruno; Winkler, Tammo; Blum, Wolfgang; Kriemler, Hans-Peter; Miller, William Russell; Faigle, Johann Werner. 2001. Pharmacokinetics and metabolism of formestane in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 39-47.
  • Lønning, Per Eystein; Sørlie, Therese; Perou, C. M.; Brown, P. O; Botstein, David; Børresen-Dale, Anne-Lise. 2001. Microarrays in primary breast cancer ¿ lessons from chemotherapy studies. Endocrine-related cancer. Endocrine-Related Cancer. 259-263.
  • Lønning, Per Eystein; Sørlie, Therese; Perou, Chuck M.; Brown, Patrick O.; Bostein, David; Børresen-Dale, Anne-Lise. 2001. Microarrays in primary breast cancer -lessons from chemotherapy studies. Endocrine-Related Cancer. 259-263.
  • Geisler, Jürgen; Detre, Simone; Berntsen, Hildegunn; Ottestad, Lars; Lindtjørn, Bernt; Dowsett, Mitch; Lønning, Per Eystein. 2001. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clinical Cancer Research. 1230-1236.
  • Lønning, Per Eystein; Taylor, Paul D.; Anker, Gun; Iddon, Julie; Wie, Liv; Jørgensen, Linn-Marie; Mella, Olav; Howell, Anthony. 2001. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment. 111-116.
  • Lønning, Per Eystein. 2001. Exemestane: a review of its clinical efficacy and safety. Breast. 198-208.
  • Helle, Svein Inge; Geisler, Jürgen; Anker, Gun; Leirvaag, B.; Holly, Jeffrey M.P.; Lønning, Per Eystein. 2001. Alterations in the insulin-like growth factor-system during treatment with diethylstilbestrol in patients with metastatic breast cancer. British Journal of Cancer. 147-151.
  • Laake, K.; Vu, P.; Andersen, T.I.; Erikstein, Bjørn; Kåresen, Rolf; Lønning, Per Eystein; Skovlund, E.; Børresen-Dale, Anne-Lise. 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • Laake, K; Vu, P; Andersen, TI; Eriksstein, Bjørn; Kåresen, Rolf; Lønning, Per Eystein; Skovlund, E; Børresen-Dale, Anne-Lise. 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • Lønning, Per Eystein. 2000. Pharmacology and clinical experience with exemestane. Expert Opinion on Investigational Drugs. 1897-1905.
  • Lønning, Per Eystein. 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • Lønning, Per Eystein. 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • Kristensen, VN; Harada, N; Yoshimura, N.; Haraldsen, E; Lønning, Per Eystein; Eriksstein, Bjørn; Kåresen, Rolf; Kristensen, T; Børresen-Dale, Anne-Lise. 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • Lønning, Per Eystein. 2000. Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
  • Lønning, Per Eystein. 2000. Endocrine therapy for treatment of breast cancer. Polish Oncology. 50-53.
  • Lønning, Per Eystein. 2000. Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
  • Lønning, Per Eystein; Bajetta, E; Murray, R; Tubiana-Hulin, M.; Eisenberg, PD; Massimini, G; Celio, L; Pitt, P; Fowst, C; Arkhipov, A; Di Salle, E.; Polli, A. 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • Geisler, Jürgen; Berntsen, Hildegunn; Lønning, Per Eystein. 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • Geisler, Jürgen; Berntsen, Hildegunn; Lønning, Per Eystein. 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • Lønning, Per Eystein; Johnsen, H; Geisler, Stephanie; Aas, T; Smith-Sørensen, B; Akslen, Lars A.; Børresen-Dale, AL. 1999. TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • Lønning, Per Eystein; Johnsen, H; Geisler, Stephanie; Aas, T; Smith-Sørensen, B; Akslen, A; Børresen-Dale, AL. 1999. TP53 as a predictor of response to chemotherapy in breast cancer. Review. European School of Oncology Scientific Updates. 73-88.
  • Lønning, Per Eystein; Johnsen, H; Geisler, Stephanie; Aas, Turid; Smith-Sørensen, B; Akslen, Lars A.; Børresen-Dale, AL. 1999. TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
  • Love, RR; Anker, Gun Birgitta; Yang, Y; Refsum, Helga; Ueland, Per Magne; Lønning, Per Eystein. 1999. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • Love, RR; Anker, Gun Birgitta; Yang, Y; Refsum, Helga; Ueland, Per Magne; Lønning, Per Eystein; Lien, Ernst Asbjørn. 1999. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • Diamandis, EP; Helle, Svein Inge; Yu, H; Melegos, DN; Lundgren, S; Lønning, Per Eystein. 1999. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer. 891-898.
  • Geisler, Jürgen; Ormsjø, I; Helle, Svein Inge; Ekse, Dagfinn; Silsand, T; Lønning, Per Eystein. 1999. Plasma estrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. Endocrinology. 265-270.
  • Geisler, Stephanie; Lønning, Per Eystein; Aas, T; Johnsen, H; Fluge, Ø; Haugen, Dagny R. Faksvåg; Lillehaug, Johan; Akslen, Lars A.; Børresen-Dale, AL. 1999. Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • Helle, Svein Inge; Lundgren, S; Geisler, Stephanie; Ekse, Dagfinn; Holly, Jeff M.P.; Lønning, Per Eystein. 1999. Effect of treatment with megestrol acetate on the IGF-system: Time and dose dependency. European Journal of Cancer. 1070-1075.
  • Lønning, Per Eystein. 1999. Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocrine-Related Cancer. 251-257.
  • Kristensen, VN; Haraldsen, EK; Anderson, KB; Lønning, Per Eystein; Erikstein, B; Kåresen, R; Gabrielsen, OS; Børresen-Dale, AL. 1999. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to SP-1. Cancer Research. 2825-2828.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Aakvaag, Asbjørn; Lien, Ernst Asbjørn. 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Aakvaag, Asbjørn; Lien, Ernst Asbjørn. 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Anker, Gun Birgitta; Aakvaag, Asbjørn; Lønning, Per Eystein; Lien, Ernst Asbjørn. 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Lønning, Per Eystein. 1998. Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • Lønning, Per Eystein; Geisler, Jürgen; Dowsett, Mitch. 1998. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
  • Helle, Svein Inge; Geisler, Jürgen; Poulsen, J.P.; Hestdal, K.; Meadows, K.A.; Collins, W.; Tveit, K.M.; Viste, Asgaut; Holly, Jeff M.P.; Lønning, Per Eystein. 1998. Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
  • Guttormsen, Anne Berit; Ueland, Per Magne; Lønning, Per Eystein; Mella, Olav; Refsum, Helga. 1998. Kinetics of total plasma homocysteine during basal conditions. Clinical Chemistry. 1886-1891.
  • Guttormsen, Anne Berit; Ueland, Per Magne; Lønning, Per Eystein; Mella, O.; Refsum, Helga. 1998. Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Guttormsen, Anne Berit; Ueland, Per Magne; Lønning, Per Eystein; Mella, Olav; Refsum, Helga. 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Helle, Svein Inge; Jonat, W.; Giurescu, M.; Ekse, Dagfinn; Holly, Jeff M.P.; Lønning, Per Eystein. 1998. Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
  • Berntsen, Hildegunn; Ekse, Dagfinn; Netteland, Bjørn; Berge, Rolf Kristian; Svardal, Asbjørn; Johannessen, Dag Clement; Lønning, Per Eystein. 1998. Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
  • Haarstad, H.; Lønning, Per Eystein; Gundersen, S.; Wist, E.; Raabe, N.; Kvinnsland, Steinar. 1998. Influence of droloxifene on metastatic breast cancer as first line endocrine treatment. Acta Oncologica. 365-368.
  • Geisler, Jürgen; Lundgren, S.; Berntsen, Hildegunn; Greaves, J.L.; Lønning, Per Eystein. 1998. Influence of dexaminoglutethimide, optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patie. Journal of Clinical Endocrinology and Metabolism. 2687-2693.
  • Haarstad, H.; Lønning, Per Eystein; Gundersen, SG.; Wist, Erik; Raabe, Nils K.; Kvinnsland, Stener. 1998. Influence of Droloxifene on Metastatic Breast Cancer as First Line Endocrine Treatment. Acta Oncologica. 365-368.
  • Geisler, Jürgen; King, N.; Anker, Gun Birgitta; Ornati, G.; Di Salle, E.; Lønning, Per Eystein. 1998. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
  • Geisler, Jürgen; Geisler, Stephanie; Lønning, Per Eystein; Småland, Rune; Tveit, Kjell Magne; Refsum, Helga; Ueland, Per Magne. 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • Geisler, Jürgen; Geisler, Stephanie; Lønning, Per Eystein; Småland, Rune; Tveit, K. M.; Refsum, Helga; Ueland, Per Magne. 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • Lønning, Per Eystein. 1998. Aromatase inhibitors and their future role in postmenopausal women with early breast cancer. British Journal of Cancer. 12-15.
  • Helle, Svein Inge; Anker, Gun Birgitta; Meadows, K.A.; Holly, Jeff M.P.; Lønning, Per Eystein. 1998. Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas. 259-265.
  • Lønning, Per Eystein; Geisler, Jürgen; Johannessen, Dag Clement; Ekse, D. 1997. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
  • Lønning, Per Eystein; Paridaens, R; Thürlimann, B; Piscitelli, G; di Salle, E. 1997. Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
  • Johannessen, Dag Clement; Engan, T; di Salle, E; Zurlo, MG; Paolini, J; Ornati, G; Piscitelli, G; Kvinnsland, Stener; Lønning, Per Eystein. 1997. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
  • Lien, Ernst Asbjørn; Anker, Gun Birgitta; Lønning, Per Eystein; Refsum, Helga; Ueland, Per Magne. 1997. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Lien, Ernst Asbjørn; Anker, Gun Birgutta; Lønning, Per Eystein; Refsum, Helga; Ueland, Per Magne. 1997. Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Geisler, Jürgen; Engelsen, Bernt; Berntsen, H; Geisler, Stephanie; Lønning, Per Eystein. 1997. Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Geisler, Jürgen; Engelsen, Bernt; Geisler, Stephanie; Lønning, Per Eystein. 1997. Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Paulsen, Trond H; Aas, Turid; Børresen, A-L; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Paulsen, Trond H; Aas, Turid; Børresen, Anne-Lise; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Dowsett, M; Lønning, Per Eystein. 1997. Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
  • Ellis, PA; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Aas, T; Geisler, Stephanie; Akslen, Lars A.; Salter, I; Smith, IE; Dowsett, M. 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Ellis, PA; Lønning, Per Eystein; Aas, Turid; Børresen, AL; Geisler, Stephanie; Akslen, Lars A.; Salter, J; Smith, IE; Dowsett, M. 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Ellis, PA; Lønning, Per Eystein; Aas, Turid; Børresen, AL; Geisler, L; Akslen, Lars A.; Salter, J; Smith, IE; Dowsett, M. 1997. Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Geisler, Jürgen; Johannessen, Dag Clement; Anker, Gun Birgitta; Lønning, Per Eystein. 1996. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. European Journal of Cancer. 789-792.
  • Aas, T; Børresen, A-L; Geisler, D; Smidth-Sørensen, B; Johnsen, H; Varhaug, Jan Erik; Akslen, Lars A.; Lønning, Per Eystein. 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Aas, Turid; Børresen, Anne-Lise; Geisler, Stephanie; Smith-Sørensen, Birgitte; Johnsen, Hilde; Varhaug, Jan Erik; Akslen, Lars A.; Lønning, Per Eystein. 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Lundgren, Steinar; Helle, Svein Inge; Lønning, Per Eystein. 1996. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clinical Cancer Research. 1515-1521.
  • Aas, Turid; Geisler, Stephanie; Paulsen, Trond H; Børresen, AL; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Aas, Turid; Geisler, S.; Paulsen, Taran; Børresen-Dale, Anne-Lise; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Aas, Turid; Geisler, Stephanie; Paulsen, Trond H; Børresen, Anne-Lise; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Lønning, Per Eystein. 1996. Pharmacology of new aromatase inhibitors. Breast. 202-208.
  • Helle, Svein Inge; Lønning, Per Eystein. 1996. Insulin-like growth factors in breast cancer. Acta Oncologica. 19-22.
  • Helle, Svein Inge; Holly, Jeff M. P.; Tally, Michael; Hall, Kerstin; van der Stappen, Jos W.J.; Lønning, Per Eystein. 1996. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. International Journal of Cancer, Predictive Oncology. 335-339.
  • Lønning, Per Eystein; Helle, Svein Inge; Johannessen, Dag Clement; Ekse, Dagfinn; Adlercreutz, Herman. 1996. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
  • Helle, Svein Inge; Anker, Gun Birgitta; Tally, Michael; Hall, Kerstin; Lønning, Per Eystein. 1996. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
  • Geisler, Jürgen; King, N.; Dowsett, M.; Ottestad, L.; Lundgren, S.; Walton, P.; Kormeset, P. O.; Lønning, Per Eystein. 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Geisler, Jürgen; King, N.; Ottestad, L.; Lundgren, S.; Walton, P.; Kormeset, P. O.; Lønning, Per Eystein. 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Frost, Victoria J.; Helle, Svein Inge; Lønning, Per Eystein; van der Stappen, Jos W. J.; Holly, Jeff M. P. 1996. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF)I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. Journal of Clinical Endocrinology and Metabolism. 2216-2221.
  • Helle, Svein Inge; Omsjø, I. H.; Hughes, S. C. Cwyfan; Botta, L.; Hüls, G.; Holly, Jeff M.P.; Lønning, Per Eystein. 1996. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study. Clinical Endocrinology. 727-732.
  • Lønning, Per Eystein. 1996. Aromatase inhibition for breast cancer treatment. Acta Oncologica. 38-43.
  • Lønning, Per Eystein; Helle, Svein Inge; Johannessen, Dag Clement; Adlercreutz, Herman; Lien, Ernst Asbjørn; Tally, M; Eske, Dagfinn; Fotsis, T; Anker, Gun Birgitta; Hall, K. 1995. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Lønning, Per Eystein; Johannesen, Dag Clement; Helle, Svein Inge; Adlercreutz, Herman; Lien, Ernst Asbjørn; Ekse, Dagfinn; Anker, Gun Birgitta; Hall, K.J. 1995. Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Ueland, Per Magne; Refsum, Helga; Lien, Ernst Asbjørn. 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Ueland, Per Magne; Refsum, Helga; Lien, Ernst Asbjørn. 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Engan, T; Krane, J; Johannessen, Dag Clement; Lønning, Per Eystein; Kvinnsland, Stener. 1995. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Research and Treatment. 287-297.
  • Helle, Svein Inge; Lønning, Per Eystein. 1995. Insulin-like growth factors in breast and prostatic cancer. Endocrine-Related Cancer. 153-169.
  • Lønning, Per Eystein; Helle, Svein Inge; Johannesen, Dag Clement; Adlercreutz, Herman; Lien, Ernst Asbjørn; Tally, M.; Ekse, Dagfinn; Fotsis, T.; Anker, Gun Birgitta; Hall, K.J. 1995. Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Lønning, Per Eystein; Johannessen, Dag Clement; Lien, Ernst Asbjørn; Eske, Dagfinn; Fotsis, T; Adlercreutz, Herman. 1995. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Geisler, Jürgen; Eske, Dagfinn; Hösch, S; Lønning, Per Eystein. 1995. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 193-195.
  • Lien, Ernst Asbjørn; Anker, Gun Birgitta; Lønning, Per Eystein; Ueland, Per Magne. 1995. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Lien, Ernst Asbjørn; Anker, Gun Birgitta; Lønning, Per Eystein; Ueland, Per Magne. 1995. Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Lønning, Per Eystein; Helle, Svein Inge; Frost, VJ; Holly, Jeff M.P.; Hall, K. 1995. Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer? Endocrine-Related Cancer. 127-130.
  • Lien, Ernst Asbjørn; Johannesen, D. C.; Aakvaag, A.; Lønning, Per Eystein. 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Lønning, Per Eystein; Hall, K.; Aakvaag, A.; Lien, Ernst Asbjørn. 1992. Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Lønning, Per Eystein; Hall, K.; Aakvaag, A.; Lien, Ernst Asbjørn. 1992. Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Lønning, Per Eystein; Lien, E.; Lundgren, S.; Kvinnsland, Steinar. 1992. Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • Lønning, Per Eystein; Lien, E.; Lundgren, S.; Kvinnsland, Steinar. 1992. Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • Lundgren, S.; Lønning, Per Eystein. 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-2. A differential effect of megestrol acetate a medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 105-109.
  • Lundgren, S.; Lønning, Per Eystein; Utaaker, E.; Aakvaag, A.; Kvinnsland, S. 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-1. General findings. Journal of Steroid Biochemistry. 99-104.
Academic lecture
  • Cao, Maria Dung; Giskeødegård, Guro F.; Bathen, Tone Frost; Sitter, Beathe; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • Cao, Maria Dung; Jiang, Lu; Krishnamachary, Balaji; Doepkens, Mailin; Vesuna, Farhad; Lønning, Per Eystein; Bhjuwalla, Zaver M.; Gribbestad, Ingrid S; Glunde, Kristine. 2011. GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • Cao, Maria Dung; Sitter, Beathe; Bathen, Tone Frost; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2010. Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • Cao, Maria Dung; Sitter, Beathe; Bathen, Tone Frost; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2010. Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • Geisler, Jürgen; Berntsen, Hildegunn; Ottestad, L; Lindtjørn, Bernt; Dowsett, Mitch; Lønning, Per Eystein. 1999. Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • Geisler, Jürgen; Berntsen, Hildegunn; Ottestad, J; Lindtjørn, Bernt; Dowsett, Mitch; Lønning, Per Eystein. 1999. Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • Geisler, Jürgen; Lønning, Per Eystein; Dowsett, M.; King, N.; Lundgren, L.; Ottestad, L.; Kormeset, P. O.; Walton, P. L. 1995. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • Johannessen, Dag Clement; Engan, T.; Kvinnsland, S.; Lønning, Per Eystein. 1994. Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • Helle, Svein Inge; Frost, V. J.; Holly, Jeff M.P.; Lønning, Per Eystein. 1994. Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Academic anthology/Conference proceedings
  • Sørlie, Therese; Børresen-Dale, Anne-Lise ; Lønning, Per Eystein; Brown, P. O; Botstein, David. 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Abstract
  • Lønning, Per Eystein. 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • Hans, Volkmar; Evans, Dean B.; Lønning, Per Eystein; Geisler, Jurgen. 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • Haynes, B; Straume, Anne Hege; Geisler, Jurgen; Ahern, R; Lonning, PE; Dowsett, M. 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • Lønning, Per Eystein. 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • Lønning, Per Eystein. 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • Gjerde, Jennifer Fernandez; Geisler, Jurgen; Lundgren, Steinar; Ekse, Dagfinn; Breilid, Harald; Hauglid, M; Varhaug, EJ; Steen, Vidar Martin; Lonning, PE; Lien, Ernst Asbjørn. 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Busch, Christian; Geisler, Jurgen; Lillehaug, Johan R.; Lønning, Per Eystein. 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • Lønning, Per Eystein. 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • Gjerde, Jennifer Fernandez; Geisler, Jurgen; Lundgren, Steinar; Ekse, Dagfinn; Breilid, Harald; Hauglid, Marianne; Varhaug, Jan Erik; Mellgren, Gunnar; Steen, Vidar Martin; Lønning, Per Eystein; Lien, Ernst Asbjørn. 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Staalesen, Vidar; Knappskog, Stian; Geisler, Stephanie; Baumbusch, L; Børresen-Dale, Anne-Lise; Lillehaug, Johan; Lønning, Per Eystein; Lonning, PE. 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Academic literature review
  • Dowsett, Mitch; Lønning, Per Eystein; Davidson, Nancy E. 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. 1580-1583.
  • Lønning, Per Eystein. 2015. Estradiol measurement in translational studies of breast cancer. 26-31.
  • Austreid, Eilin; Lønning, Per Eystein; Eikesdal, Hans Petter. 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 681-700.
  • Lønning, Per Eystein; Knappskog, Stian. 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. 5315-5330.
  • Lønning, Per Eystein; Eikesdal, Hans Petter. 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. R183-R201.
  • Knappskog, Stian; Lønning, Per Eystein. 2012. P53 and its molecular basis to chemoresistance in breast cancer. S23-S30.
  • Lønning, Per Eystein. 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. 503-514.
  • Lønning, Per Eystein; Haynes, Ben P.; Straume, Anne Hege; Dunbier, Anita; Helle, Hildegunn; Knappskog, Stian; Dowsett, Mitch. 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. 4948-4958.
  • Mouridsen, Henning T; Lønning, Per Eystein; Beckmann, Matthias W; Blackwell, Karen; Doughty, Julie; Gligorov, Joseph; Llombart-Cussac, Antonio; Robidoux, Andre; Thurlimann, Beat; Gnant, Michael. 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. 1825-1836.
  • Lønning, Per Eystein. 2010. Molecular basis for therapy resistance. 284-300.
  • Lønning, Per Eystein. 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? 527-535.
  • Christoffersen, Thoralf; Guren, Tormod K.; Spindler, Karen-Lise Garm; Dahl, Olav; Lønning, Per Eystein; Gjertsen, Bjørn Tore. 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 6-22.
  • Lønning, Per Eystein. 2009. Additive endocrine therapy for advanced breast cancer - back to the future. 1092-1101.
  • Lønning, Per Eystein; Geisler, Jurgen. 2008. Indications and limitations of third-gene ration aromatase inhibitors. 723-739.
  • Lønning, Per Eystein; Knappskog, Stian; Staalesen, Vidar; Chrisanthar, Ranjan; Lillehaug, Johan. 2007. Breast cancer prognostication and prediction in the postgenomic era. 1293-1306.
  • Geisler, Jürgen; Lønning, Per Eystein. 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. 53-61.
  • Lønning, Per Eystein. 2004. Aromatase inhibitors in breast cancer. 179-189.

More information in national current research information system (CRIStin)

Fields of competence